Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient

Marta Gubbiotti; Barbara Pistilli; Marianna Tudini; Giovanni Benedetti; Eva Galizia; Marco Rusiello; Luciano Latini

doi:10.2217/fon.15.148

Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient

Marta Gubbiotti, Barbara Pistilli, Marianna Tudini, Giovanni Benedetti, Eva Galizia, Marco Rusiello, Luciano Latini

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

3 Citations (Scopus)

Résumé

The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m² on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.

langue originale	Anglais
Pages (de - à)	17-22
Nombre de pages	6
journal	Future Oncology
Volume	11
Numéro de publication	15s
Les DOIs	https://doi.org/10.2217/fon.15.148
état	Publié - 1 août 2015
Modification externe	Oui

Accès au document

10.2217/fon.15.148

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{7e9734455781496487a9dd42b98ea7d0,

title = "Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient",

abstract = "The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m2 on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.",

keywords = "brain metastases, breast cancer, eribulin, retinal metastases",

author = "Marta Gubbiotti and Barbara Pistilli and Marianna Tudini and Giovanni Benedetti and Eva Galizia and Marco Rusiello and Luciano Latini",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2015",

month = aug,

day = "1",

doi = "10.2217/fon.15.148",

language = "English",

volume = "11",

pages = "17--22",

journal = "Future Oncology",

issn = "1479-6694",

number = "15s",

}

TY - JOUR

T1 - Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient

AU - Gubbiotti, Marta

AU - Pistilli, Barbara

AU - Tudini, Marianna

AU - Benedetti, Giovanni

AU - Galizia, Eva

AU - Rusiello, Marco

AU - Latini, Luciano

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m2 on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.

AB - The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m2 on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.

KW - brain metastases

KW - breast cancer

KW - eribulin

KW - retinal metastases

UR - http://www.scopus.com/inward/record.url?scp=84952659396&partnerID=8YFLogxK

U2 - 10.2217/fon.15.148

DO - 10.2217/fon.15.148

M3 - Article

C2 - 26235260

AN - SCOPUS:84952659396

SN - 1479-6694

VL - 11

SP - 17

EP - 22

JO - Future Oncology

JF - Future Oncology

IS - 15s

ER -